Swiss Medical Group Holding Acquires CoreMedica Europe
Swiss Medical Group (SMG) Holding Luxembourg S.A., leading the development of STARKS Age-Management in Europe and Asia, announced today the acquisition of CoreMedica Europe, to expand in Europe and the rest of the world.
CoreMedica Europe recently made the headlines in Switzerland for combining a COVID-19 Screening Test and Immunity profile with its existing home self-collection kit that allows customers to collect a few drops of blood and send them by mail to CoreMedica Europe’s accredited laboratory in Geneva to screen the anti-SARS-COV-2 IgG antibody and assess any previous infection to SARS-COV-2, the virus responsible for COVID disease, and analyze a set of 5 key biomarkers known to support the immune system (vitamin D, zinc, magnesium, copper, selenium) so as to receive personalized actionable recommendations to help patients build up their natural defenses against the effects of a next potential viral infection.
“In this epidemic and containment context the essential objective of CoreMedica Europe is to allow a patient to collect a few drops of blood at home without involving healthcare personnel and to carry out this serology test in a controlled laboratory environment. From 3 drops of blood taken from your fingertip, our test can tell if someone has been infected with the coronavirus in the past and can help to clarify their general immune status by assessing key markers in the blood” says Dr Jean-Marc Leroux, CEO of CoreMedica Europe.
“With this test we are putting our expertise in testing and personalized recommendations at the service of the fight against COVID 19, with a set of key biomarkers known to support someone's immune system and a precise summary of the results so as to help them strengthen their natural defenses against the effects of the next potential viral infection” says Pierre-Edouard Sottas, CSO of CoreMedica Europe.
CoreMedica expertise goes beyond COVID-19 serological testing and its competitive advantage lies in the personalized analysis of biological data on three main axes:
- Collection of health data by means of home self-collection kits of a few drops of blood,
- Analysis of large quantities of bio-markers, with a unique know-how developed over several years,
- Personalized recommendations using patented technology applied in the field of immunity, nutrition, sports, and anti-aging.
“The objective of SMG is to integrate CoreMedica Europe's unique expertise in the field of blood tests and personalized recommendations into the network of anti-aging clinics that SMG is developing in Europe, so as to improve P4 models in the field of anti-aging and foster preventative care, thereby reducing the costs of treatments”, says Francois Marland, Chairman and CEO of Swiss Medical Group and Chairman of CoreMedica Europe.
SMG has already tested the market with age-management clinics in France, Italy and Greece, the on-going development of eight more clinics in Germany in 2020-2021, and a roll-out plan of 52 age-management clinics in Europe by 2025, developed either by organic growth or by the acquisition of well-known practices.
As part of the deal, SMG took over the operations of CoreMedica Europe in Geneva, the team and its expertise, the authorizations, and all associated patents, algorithms and other intellectual property, as well as negotiated an exclusive distribution agreement in North America with CoreMedica Laboratories Inc., a CAP accredited and CLIA certified laboratory based in the United States.
About Swiss Medical Group:
As a backdrop, Swiss Medical Group Holding invests in the development of companies and clinics in the health sector, including STARKS Age Management, whose activity is to offer a one-stop-shop solution in terms of internal and external age management, including hair, aesthetics, orthopedics, blood tests, digital analysis and health maintenance recommendations, as well as the distribution of well-being or anti-aging products, protocols and therapies.
About CoreMedica Europe:
As a background, BioKaizen, founded in Switzerland and born from developers of the athlete biological passport to detect drug use for the World Anti-Doping Agency and the International Olympic Committee, has developed a mass spectrometry technology platform to identify a patient’s nutritional profile using dried blood. Following the merger with BioKaizen in 2018, CoreMedica expanded its offering globally to include personalized nutrition and sport performance information that empowers customers with information to help actively manage their health.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005730/en/
Contact information
Maximilien Marland
Swiss Medical Group Holding Luxembourg
Tel: +41 78 898 3002
Info@starksglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IO Interactive Announces Olivier Perbet as Chief Marketing and Revenue Officer2.7.2025 16:00:00 EEST | Press release
IO Interactive, the award-winning developer and publisher behind the globally-acclaimed HITMAN franchise, is proud to announce the promotion of Olivier Perbet to Chief Marketing and Revenue Officer (CMRO). In this expanded role, Olivier will now oversee both marketing and revenue operations across the studio’s portfolio, including Digital and Physical Sales, Business Development, and go-to-market strategy, as IOI enters an exciting new chapter of growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702593970/en/ © IO Interactive A/S Olivier joined IO Interactive as Chief Marketing Officer in 2023, bringing with him over 20 years of experience across gaming, consumer electronics, and entertainment. Since then, he has played a key role in scaling IOI’s global publishing capabilities, supporting the set-up of IOI Partners and delivering standout campaigns. Under Olivier’s leadership, IOI recently celebrated major milestone
Seoul Semiconductor’s World’s No.1 Technology Targets EV and Autonomous Vehicle Markets2.7.2025 16:00:00 EEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), the world’s No. 1 company in LED backlight, announced on July 2nd that its proprietary No-wire technology, WICOP, has been supplied to the automotive market in the form of Mini LED displays since May. As the world’s first No-wire LED technology, WICOP has already proven its performance across various applications—including smartphones, TVs, lighting, and automotive headlamps. Recognized for its superior brightness and durability even in extreme automotive environments, WICOP has now officially entered the automotive display market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702244031/en/ [Figure] Comparison of 1st-Generation LED and 2nd-Generation ‘WICOP’ Structure (Image: Seoul Semiconductor) The No-wire WICOP technology applied to Mini LED enables ultra-slim display designs, making it ideal for full array local dimming. This allows for deeper contrast and higher bright
Barilla Launches 7th Edition of Good Food Makers to Shape the Future of Food2.7.2025 15:20:00 EEST | Press release
Barilla officially opens applications for Good Food Makers 2025, its open innovation program dedicated to startups and innovative companies focused on creating a more sustainable and connected food system. Now in its seventh edition, the program welcomes a new format — Good Food Makers – ECOSYSTEM — developed in collaboration with Almacube, the innovation hub of the University of Bologna and Confindustria Emilia. This year’s goal is to build a true innovation ecosystem by involving Barilla’s value chain partners and accelerating the adoption of emerging technologies. Three selected startups will join a four-week co-development journey with Barilla professionals and partner companies, working side-by-side to create impactful solutions across the entire food chain — from field to fork. Applications are open until the end of July, with the program running from September to January 2026, concluding with the Innovation Day. “Good Food Makers reflects our commitment to open innovation that g
SE Labs Award Reinforces NetApp Status as the Most Secure Storage on the Planet2.7.2025 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it was recognized as a standout performer in cybersecurity in the SE LABS ® Awards 2025. NetApp won the 2025 SE Labs Award for Enterprise Data Protection, validating NetApp’s status as the most secure storage on the planet. This recognition as a winner of a 2025 SE Labs Award is a result of NetApp’s exceptional innovation in cyber resiliency to deliver NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI), which was tested and validated by SE Labs. NetApp ARP/AI demonstrated 99 percent detection of tested, advanced full-file encryption ransomware attacks with zero false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue. “Great security doesn’t just happen—it’s built, tested and proven,” says Simon Edwards, Founder and CEO of SE Labs. “Behind every high performing security product is a team committed to excel
CroíValve Announces Funding from Horizon Europe EIC Accelerator2.7.2025 15:00:00 EEST | Press release
CroíValve, a pioneering medical device company innovating a better way to help more patients suffering from Tricuspid Regurgitation (TR), was awarded funding from Horizon Europe’s European Innovation Council (EIC) Accelerator Programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702306192/en/ DUO™ Transcatheter Tricuspid System Part of the EU’s Horizon Europe 2021-2027 Research and Innovation Programme, the EIC Accelerator Programme provides transformational funding to high-potential, high-risk start-ups, scale-ups and subject matter experts. This award includes grant funding of €2.5 million, combined with an equity investment of €10 million in CroiValve’s next financing. The latest competition included 959 applications, with only 40 awards across 16 countries. Almost one third of the selected companies are led by a woman and CroiValve are incredibly proud to be one of this group. “Securing European Innovation Council
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom